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Abstract
Several protein transfection reagents are commercially available and are powerful tools for elucidating function of a
protein in a cell. Here we described protein transfection studies of the commercially available reagents, Pro-
DeliverIN, Xfect, and TuboFect, using Huh-7 multicellular tumor spheroid (MCTS) as a three-dimensional in vitro
tumor model. A cellular uptake study using specific endocytosis inhibitors revealed that each reagent was
internalized into Huh-7 MCTS by different mechanisms, which were the same as monolayer cultured Huh-7 cells. A
certain amount of Pro-DeliverIN and Xfect was uptaken by Huh-7 cells through caveolae-mediated endocytosis,
which may lead to transcytosis through the surface-first layered cells of MCTS. The results presented here will help in
the choice and use of protein transfection reagents for evaluating anti-tumor therapeutic proteins against MCTS
models.
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Introduction
Multicellular tumor spheroid (MCTS) is known to be a very
useful three-dimensional in vitro tumor model, which represents
the morphological and functional features of in vivo avascular
solid tumors [1–3]. MCTS is characterized by actively
proliferating outer cell layers and hypoxic and quiescent inner
cells. Compared to monolayer cultured cells, a long-term
culture can be achieved by spheroid cell cultures with the
sufficient maintenance of their functions. Therefore, MCTS is a
good experimental model located between an in vitro
monolayer cultured cell model and in vivo animal model. This
model has been widely used not only for screening ani-tumor
drug candidates [4,5], but also for investigating drug delivery
systems (DDS) [6–9]. The deep percolation of anti-tumor drugs
and their DDS into tumor tissues is necessary for successful
therapy, and this can be evaluated using MCTS models.
Proteins are one of the most important biomacromolecules in
all living cells. The application of proteins to research has
ranged from biochemical experiments to drug discoveries.
Proteins are easily degraded by protease and deactivated in or
out of cells. A major key for the success of delivering proteins
to cells directed to biochemical and drug discovery studies is
the development of protein delivery systems with high
efficiency and negligible cytotoxicity [10,11]. Several protein
transfection reagents are commercially available due to the
extensive development of excellent delivery systems [12,13].
Their reagents are powerful tools for elucidating the function of
a protein in a cell and controlling cellular functions by an
introduced protein.
We recently reported the intracellular internalization
mechanism of three different commercially available protein
transfection reagents, the lipid-based Pro-DeliverIN, peptide-
based Xfect, and cationic polymer-based TurboFect [14].
These reagents were internalized into monolayer cultured
HeLa cells by different mechanisms, which may be helpful in
choosing and using protein transfection reagents for
experiments. To gain further information into the biological
properties of these reagents, we reused Pro-DeliverIN, Xfect,
and TurboFect in this study, and evaluated their complexes
with bovine serum albumin (BSA) against human hepatoma
Huh-7 MCTS models as well as monolayer cultured cell
models. We have already reported that Huh-7 cells were good
models for MCTS [8,9]. Less attention has been paid to studies
on protein transfection reagents using MCTS models. Cellular
uptake studies using specific inhibitors of endocytosis and
confocal laser scanning microscope (CLSM) observations
clarified the internalization routes and final localization of each
complex in Huh-7 MCTS. The results obtained here may be
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informative for using protein transfection reagents against
MCTS to screen and evaluate anti-tumor therapeutic proteins.
Materials and Methods
Materials
Pro-DeliverIN was purchased from OZ Biosciences
(Marseille, France). Xfect was obtained from Clontech
Laboratories, Inc. (Palo Alto, CA, USA). TurboFect was
purchased from Fermentas (Glen Burnie, MD, USA).
Dulbecco’s modified Eagle’s medium (DMEM), bovine serum
albumin (BSA), fluorescein isothiocyanate conjugate BSA
(FITC-BSA), filipin III from Streptomyces filipinesis, and
amiloride hydrochloride were purchased from Sigma-Aldrich
Co. (ST. Louis, MO, USA). Heparin, Cell lysis buffer M, and
sucrose were the products of Wako Pure Chem. Co., Ltd.
(Osaka, Japan). Hoechst 33342 was purchased from Dojindo
Laboratories (Kumamoto, Japan).
Preparation of protein transfection reagent/BSA
complex
Each protein transfection reagent/BSA or FITC-BSA complex
was prepared according to the manufacture’s protocols and the
previous study [14]. Briefly, 1.0 μL of Pro-DeliverIN reagent, 3.0
μL of 1X Xfect protein transfection reagent stock solution, and
0.8 μL of TurboFect protein transfection reagent were used to
prepare complexes containing 1.0 μg of BSA or FITC-BSA,
respectively.
Dynamic light scattering (DLS) measurement
The size of BSA complexes was evaluated by DLS using
Nano ZS (ZEN3600, Malvern Instruments, Ltd., UK). A He–Ne
ion laser (633 nm) was used as the incident beam. The data
obtained at a detection angle of 173° and a temperature of
37°C were analyzed by a cumulant method to obtain the
hydrodynamic diameters and polydispersity index (PDI) (μ/Γ2)
of complex. The results are presented as the mean and
standard deviation obtained 3 measurements.
Zeta-potential measurement
The zeta-potential of BSA complexes was evaluated by the
laser-Doppler electrophoresis method using Nano ZS with a
He–Ne ion laser (633 nm). The zeta-potential measurements
were carried out at 37°C. A scattering angle of 173° was used
in these measurements. The results are presented as the
mean and standard deviation obtained 3 measurements.
Cell culture and preparation of multicellular tumor
spheroid (MCTS)
Human hepatoma Huh-7 cells (JCRB Cell Bank, Osaka,
Japan) were maintained in DMEM supplemented with 10%
fetal bovine serum in a humidified atmosphere containing 5%
CO2 at 37°C. MCTS was prepared by using a 96-well culture
plate designed for spheroid formation (Sumiloncelltight,
Sumitomo Bakelite, Tokyo, Japan) as reported previously [8,9].
Briefly, 200 μL of the cell suspension (2,500 cells/mL) was
seeded onto a 96-well culture plate. After overnight incubation,
MCTS with a diameter of ca. 150 μm was spontaneously
formed in each well.
Cellular uptake using monolayer cultured cells
Each protein transfection reagent/FITC-BSA complex was
used for these experiments. Huh-7 cells were seeded onto 96-
well culture plates (10,000 cells/well) and incubated overnight
in 100 μL of medium. The medium was replaced by fresh
medium and protein transfection reagent/FITC-BSA complex
solution was then applied to each well (0.25 μg FITC-BSA/
well). After 3h incubation, the medium was removed, and cells
were washed 3 times with ice-cold PBS supplemented with
heparin (20 units/mL) and treated with Cell lysis buffer M. The
fluorescence intensity of the lysate at 515 nm (white LED
excitation) was measured by a spectrofluorometer (ND-3300,
NanoDrop, Wilmington, DE, USA) and cellular uptaken protein
(dose%) was calculated using a calibration curve. The results
are presented as the mean and standard deviation obtained
from 4 samples.
Inhibition of endocytosis using monolayer cultured
cells
Huh-7 cells were seeded onto 96-well culture plates (10,000
cells/well) and incubated overnight in 100 μL of medium. After
replacement with fresh medium in the absence or presence of
sucrose (0.4 M), amiloride (5 mM), or filipin (5 μg/mL), cells
were pre-incubated at 37°C for 30 min. Each protein
transfection reagent/FITC-BSA complex solution was then
applied to each well (0.25 μg FITC-BSA/well) and incubated for
1h (in the case of amiloride and filipin) or 3h (in the case of
sucrose). The experimental conditions were as reported
previously [14]. After each incubation time, the medium was
removed and cells were washed 3 times with ice-cold PBS
supplemented with heparin (20 units/mL) followed by treatment
with Cell lysis buffer M. The fluorescence intensity of the lysate
at 515 nm (white LED excitation) was measured by the
ND-3300. The results are presented as the mean and standard
deviation obtained from 3 samples.
Cellular uptake using MCTS
Each protein transfection reagent/FITC-BSA complex
solution was applied to each well with MCTS (0.25 μg FITC-
BSA/well). After 3h incubation, the medium was removed, and
MCTS was washed 3 times with ice-cold PBS supplemented
with heparin (20 units/mL) followed by treatment with Cell lysis
buffer M. The fluorescence intensity of the lysate was
measured by a spectrofluorometer (ND-3300, NanoDrop) and
cellular uptaken protein (dose%) was calculated using a
calibration curve. The results are presented as the mean and
standard deviation obtained from 4 samples.
Inhibition of endocytosis using MCTS
MCTS was pre-incubated at 37°C for 30 min with medium in
the absence or presence of sucrose (0.4 M), amiloride (5 mM),
or filipin (5 μg/mL). Each protein transfection reagent/FITC-
BSA complex solution was then applied to each well (0.25 μg
FITC-BSA/well) and incubated for 1h (in the case of amiloride
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and filipin) or 3h (in the case of sucrose). After each incubation
time, the medium was removed and cells were washed 3 times
with ice-cold PBS supplemented with heparin (20 units/mL)
followed by treatment with Cell lysis buffer M. The fluorescence
intensity of the lysate at 515 nm (white LED excitation) was
measured by the ND-3300. The results are presented as the
mean and standard deviation obtained from 4 samples.
Confocal laser scanning microscope (CLSM)
observations using MCTS
Each protein transfection reagent/FITC-BSA complex
solution was applied to each well with MCTS (0.25 μg FITC-
BSA/well). After 3h incubation, the medium was removed, and
spheroids were washed 3 times with ice-cold PBS
supplemented with heparin (20 units/mL). In the case of
inhibitory experiments (Figure S2), MCTS was pre-incubated at
37°C for 30 min with medium in the absence or presence of
sucrose (0.4 M), amiloride (5 mM), or filipin (5 μg/mL). Each
protein transfection reagent/FITC-BSA complex solution was
then applied to each well (0.25 μg FITC-BSA/well) and
incubated for 1h (in the case of amiloride and filipin) or 3h (in
the case of sucrose). The intracellular distribution of the protein
transfection reagent/FITC-BSA complex was observed by a
confocal laser scanning microscope (CLSM) after staining
nuclei with Hoechst 33342. CLSM observations were
performed using an LSM 710 (Carl Zeiss, Oberlochen,
Germany) with an EC Plan-Neofluar 40X/1.3 objective (Carl
Zeiss) or Plan-Apochromat 100X/1.4 objective (Carl Zeiss) at
an excitation wavelength of 405 nm (UV laser) and an emission
wavelength of 409—484 nm for Hoechst 33342, and 488 nm
(Ar laser) and 494—542 nm for FITC-BSA.
Statistical analysis
Statistical significance was assessed by 2-tailed Student’s t-
test. P values of less than 0.05 were considered significant.
Results
Physicochemical characterization of BSA complexes
The mean size and zeta-potential of BSA complexes were
different according to the protein transfection reagents (Table
1). Xfect showed small size of 32.3 nm and positive charge of
+8.89 mV, while Pro-DeliverIN and TuboFect showed bigger
sizes of 832 and 393 nm and negative charges of –13.2 and –
25.9 mV, respectively. PDI of Pro-DeliverIN, Xfect, and
TurboFeect were 0.394, 0.342, and 0.551, which were quite
high compared to ideal monodisperse nano particles.
Table 1. Size and zeta-potential of each protein tranfection
reagent/BSA complex.
 size(nm) PDI(μ/Γ2) zeta-potential(mV)
Pro-DeliverIN 832±53 0.394±0.044 –13.2±4.3
Xfect 32.3±4.2 0.341±0.007 8.89±0.31
TurboFect 393±12 0.551±0.039 -25.9±1.0
doi: 10.1371/journal.pone.0082876.t001
Cellular uptake of BSA complexes
The cellular uptake of protein transfection reagents into
Huh-7 monolayer cultured cells and MCTS was evaluated
using FITC-conjugated BSA-incorporated complexes (Figure
1). Cell lysate treated with naked FITC-BSA showed no
fluorescence in this experiment (data not shown). In the case of
experiments using monolayer cultured cells, the cellular uptake
of Xfect and TurboFect was significantly higher than that of
Pro-DeliverIN (Figure 1A). Note that cells treated with
complexes in medium without fetal bovine serum showed
similar results (data not shown). The amounts of cellular
uptaken FITC-BSA (dose%) by Pro-DeliverIN, Xfect, and
TurboFect were 1.5, 3.0, and 3.5%, respectively. On the other
hand, MCTS treated with TurboFect was taken up more
efficiently than those with Pro-DeliverIN and Xfect (Figure 1B).
The amounts of cellular uptaken FITC-BSA (dose%) by MCTS
were markedly less than that by monolayer cultured cells, in
which Pro-DeliverIN, Xfect, and TurboFect were 0.11, 0.11,
and 0.52 dose%, respectively.
Effect of endocytosis inhibitors on the internalization of
BSA complexes
To clarify the mechanism of each complex internalization into
Huh-7 monolayer cultured cells and MCTS, inhibitory
experiments of cellular uptake were carried out using specific
endocytosis inhibitors (Figure 2). The effects of the following
endocytosis inhibitors on the internalization of complexes were
examined: sucrose (a specific inhibitor of clathrin-mediated
endocytosis); amiloride (a specific inhibitor of
macropinocytosis); and filipin (a specific inhibitor of caveolae-
mediated endocytosis) [14–16]. Similar results were obtained
from experiments using monolayer cultured cells and MCTS.
The cellular uptake of Pro-DeliverIN complexes was
significantly lowered by treatments with sucrose and filipin than
by the treatment with no additive control, which implied that the
internalization of Pro-DeliverIN complexes into Huh-7 cells
occurred via clathrin-mediated endocytosis and caveolae-
mediated endocytosis. In the case of Xfect complexes, the
amiloride treatment caused an approximately 40-50% decrease
in the amount of cellular uptake. Filipin also significantly
decreased the internalization of Xfect complexes. Xfect
complexes may be mainly internalized into Huh-7 cells via
macropinocytosis, but with the addition of caveolae-mediated
endocytosis. The results obtained on the internalization of
TurboFect complexes demonstrated that incubation in the
presence of amiloride significantly affected cellular uptake,
while that in the presence of sucrose and filipin did not. These
results indicate that the TuboFect complexes were internalized
into Huh-7 cells preferentially through macropinocytosis. It is
worth mentioning again that each transfection reagent
appeared to be internalized into Huh-7 monolayer cultured cells
and MCTS by same mechanism.
MCTS distribution of complexes
The distribution of each complex in MCTS was investigated
by CLSM equipped with 40X (Figure 3) and 100X objectives
(Figure 4) using FITC-BSA (green)-incorporated complexes.
Hoechst 33342 was used to label nuclei (blue). Using the 40X
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objective, the entire spheroid was observed from the top view
with the Z-stack mode from the top to middle positions (Figure
3A). The intensity of the observed FITC-BSA in MCTS treated
with TurboFect complexes was the highest. These results were
consistent with those of cellular uptake in Figure 1B. MCTS
treated with Pro-DeliverIN and Xfect complexes showed similar
distribution profiles to FITC-BSA, in which green fluorescence
was mainly observed in the surface-first layered cells, but was
also moderately observed in the inner layered cells. On the
other hand, TurboFect complexes displayed FITC-BSA
distribution only in the surface-first layered cells. A more
detailed observation of FITC-BSA in MCTS was carried out in
experiments using the 100X objective (Figure 4). The
distribution of FITC-BSA was confirmed not only in the
intracellular compartments, but also in the nuclei especially in
MCTS treated with TurboFect complexes. A small amount of
FITC-BSA in the Pro-DeliverIN and Xfect complexes was
observed in the inner layered cells of MCTS. MCTS treated
with TurboFect complexes showed green fluorescence only in
the surface-first layered cells. These results were consistent
with the images taken by the 40X objective.
Discussion
Protein therapy is increasingly recognized as a promising
therapy for many intractable diseases [17,18]. Many clinical
trials exploring protein therapy are currently underway and
several systems are available for clinical use [19,20]. Most
clinically used protein drugs have their functional roles in
extracellular milieu because their target molecules are
generally cell-surface receptors [21]. A next-generation protein
drug may target intracellular molecules; therefore, a major key
to success is the development of protein delivery systems that
have high delivery efficiency not only to the target tissue, but
also to the target intracellular compartment [10–13]. Several
types of protein transfection reagents are commercially
available for biochemical experiments [12,13,22]. They may not
be available for clinical use, but it is important for researchers
to know their biological properties, which may lead to the
discovery of an excellent protein drug. Recent in vitro studies
revealed that three different commercially available protein
transfection reagents, Pro-DeliverIN, Xfect, and TurboFect
were uptaken by monolayer cultured HeLa cells through
different routes [14]. To obtain further information, we herein
evaluated their protein trasfection reagents using Huh-7 MCTS
models, which are useful three dimensional in vitro avascular
tumor models.
The size and zeta-potential of BSA complexes were
measured to know their physicochemical properties (Table 1).
In general, polyion complexes between cationic polymers,
liposomes, or peptides and anionic macromolecules such as
DNA, RNA, or proteins, have positive surfaces with several
tens to several hundreds nm. Contrary to our expectation, Pro-
DeliverIN and TurboFect complexes had negative surface. We
estimated that three commercially available reagents might
include the additives, which affected the physicochemical
properties of their BSA complexes.
Figure 1.  Cellular uptake of each protein transfection reagent/FITC-BSA complex.  FITC-BSA complexes with Pro-DeliverIN,
Xfect, and TurboFect were applied to Huh-7 monolayer cultured cells (A) and MCTS (B). Error bars in the graph represent the
standard deviation, n = 4. *p<0.05 and **p<0.01. In the case of monolayer cultured cells (A), TurboFect and Xfect achieved higher
cellular uptake efficiency than that of Pro-DeliverIN. MCTS experiments revealed the higher uptake of TurboFect than of Pro-
DeliverIN and Xfect. The uptake of protein transfection reagents was markedly higher by monolayer cultured cells than by MCTS.
doi: 10.1371/journal.pone.0082876.g001
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The amount of TuboFect/FITC-BSA complexes internalized
into Huh-7 MCTS was significantly higher than that of Pro-
DeliverIN and Xfect complexes (Figure 1B). The results
obtained from experiments using monolayer cultured cells
showed that the cellular uptake of Xfect and TurboFect was
more efficient than that of Pro-DeliverIN (Figure 1A). The
amount of FITC-BSA (dose%) uptaken by MCTS was
approximately 1/7 to 1/25 that of monolayer cultured cells,
which may have been due to the number of cells used in each
experiment. Five hundred Huh-7 cells were used in one
experiment to evaluate MCTS and 10,000 cells were used in
an experiment using monolayer cultured cells. Furthermore, the
cell surface area of MCTS exposed to the medium with the
complexes was much smaller than that of monolayer cultured
cells even though the same number of cells were used. No
cytotoxicity against both monolayer cultured cells and MCTS
was observed under all experimental conditions (data not
shown).
Inhibitory experiments using specific inhibitors of endocytosis
were carried out in order to elucidate the intracellular
internalization routes of each complex against monolayer
cultured cells and MCTS (Figure 2). The results obtained from
MCTS were similar to those from monolayer cultured cells,
which were also consistent with previous results using
monolayer cultured HeLa cells. Each protein transfection
reagent may be internalized into cells through the same routes
in spite of the cell type (Huh-7 and HeLa cells) [14] and cell
morphology (monolayer cultured cells and spheroid cells). Pro-
DeliverIN complexes were preferentially internalized into Huh-7
cells via clathrin-mediated endocytosis and caveolae-mediated
endocytosis. Huh-7 cells took up Xfect complexes by
macropinocytosis and, in addition, caveolae-mediated
Figure 2.  Inhibition of endocytosis using specific inhibitors.  Effects of inhibitors (sucrose: clathrin-mediated endocytosis
inhibitor; amiloride: macropinocytosis inhibitor; filipin: caveolae-mediated endocytosis inhibitor) on the internalization of FITC-BSA
complexes with Pro-DeliverIN, Xfect, and TurboFect were evaluated using Huh-7 monolayer cultured cells (A) and MCTS (B). Error
bars in the graph represent the standard deviation, n = 3 (A) or 4 (B). *p<0.05 and **p<0.01. The results obtained from monolayer
cultured cells (A) and MCTS (B) were similar. Pro-DeliverIN appeared to be internalized into Huh-7 cells by clathrin-mediated
endocytosis and caveolae-mediated endocytosis. The uptake route of Xfect was mainly by macropinocytosis, but also slightly by
caveolae-mediated endocytosis. TurboFect was preferentially internalized into Huh-7 cells through macropinocytosis.
doi: 10.1371/journal.pone.0082876.g002
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endocytosis. On the other hand, only macropinocytosis
appeared to be the internalization route of TuboFect
complexes. Based on these results, we can choose and use an
appropriate protein transfection reagent according to the type
of experiment being conducted.
CLSM observations with nuclei staining (blue) were carried
out to clarify the distribution of each complex in MCTS (Figures
3 and 4). Figure 3B shows each complex distribution (green) in
MCTS using the 40X objective. TuboFect complexes were
distributed only in the surface-first layered cells. MCTS treated
with Pro-DeliverIN and Xfect complexes showed strong FITC-
BSA distribution in the surface-first layered cells, but modest
distribution in the inner layered cells. Figure S1 showed the
results of semi-quantification of fluorescence intensity in the
first layered cells or second layered cells. Fluorescence
intensity of TuboFect complexes in the second layered cells
were much smaller than those in the first layered cells, which is
consistent with the results in Figures 3 and 4. Two possibilities
Figure 3.  CLSM observations (40X objective) of each FITC-BSA complex using MCTS.  A: Schematic illustration of MCTS
observed in these experiments. The full size of MCTS was observed from the top view with the Z-stack mode from the top to middle
positions. The optical thickness and the distance of the confocal section from the top of MCTS were 0.60 μm and 20 μm,
respectively. B: The intra-MCTS distribution of FITC-BSA (green) complexes with Pro-DeliverIN, Xfect, and TurboFect was
observed by CLSM using the 40X objective with staining nuclei (blue) shown in A. A certain amount of FITC-BSA complexes with
Pro-DeliverIN and Xfect was observed in the inner layered cells. On the other hand, TurboFect showed FITC-BSA distribution only
in the surface-first layered cells. The scale bars represent 50 μm.
doi: 10.1371/journal.pone.0082876.g003
Figure 4.  CLSM observations (100X objective) of each FITC-BSA complex using MCTS.  A: Schematic illustration of MCTS
observed in these experiments. About one quater size of MCTS was observed from the top view. The optical thickness and the
distance of the confocal section from the top of MCTS were 0.38 μm and 20 μm, respectively. B: The intra-MCTS distribution of
FITC-BSA (green) complexes with Pro-DeliverIN, Xfect, and TurboFect was observed in detail by CLSM using the 100X objective
with staining nuclei (blue). A small amount of FITC-BSA was observed in the nuclei, especially in TurboFect. The scale bars
represent 20 μm.
doi: 10.1371/journal.pone.0082876.g004
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have been proposed for the appearance of green color in the
inner cells of MCTS. The first is that complexes went through
intercellular compartments, in which the extracellular matrix
including polysaccharides and proteins existed. It is generally
difficult for macromolecules and nano-sized particles to move
freely across the extracellular matrix [2]. The second is that
transcytosis caused percolation of the complexes. A similarity
between Pro-DeliverIN and Xfect complexes is that caveolae-
mediated endocytosis was involved in Huh-7 cellular uptake. In
addition, caveolae-mediated transcytosis has been reported to
be a possible vesicular trafficking pathway through cell barriers
[23,24]. Thus, it is reasonable to assume that some Pro-
DeliverIN and Xfect complexes could pass through the surface-
first layered cells by caveolae-mediated transcytosis. The
results obtained from CLSM observations using specific
endocytosis inhibitors were consistent with this hypothesis
(Figure S2). Filipn, which is a caveolae-mediated endocytosis
inhibitor, obviously affected on the percolation of Pro-DeliverIN
and Xfect complexes, while sucrose and amiloride did not.
CLSM observations using the 100X objective revealed a more
detailed complex distribution in MCTS, in which small amount
of complexes was colocalized in the nuclei of surface-first
layered cells (Figure 4B). The outer cell layers of MCTS
actively proliferate, which may allow the complexes to enter
nuclei during mitosis. CLSM observations were not performed
completely because it was difficult to observe deep inner
layered cells in MCTS [7,8]. However, the results obtained here
exhibited a clear decline according to the each reagent, even in
the observations of surface-second layered cells in MCTS.
In conclusion, three commercially available protein
transfection reagents, Pro-DeliverIN, Xfect, and TurboFect
were evaluated using Huh-7 cells in this study. Each reagent
had preferential cellular uptake routes, which were the same by
monolayer cultured cells and MCTS of Huh-7. In addition, the
internalization mechanism affected the distribution of each
reagent in MCTS, that is, caveolae-mediated endocytosis/
transcytosis delivered Pro-DeliverIN and Xfect complexes to
the inner cells. These results may be helpful in choosing and
using protein transfection reagents for in vitro monolayer
cultured cells and MCTS experiments with the aim of
evaluating anti-tumor therapeutic proteins.
Supporting Information
Figure S1.  Semi-quantitative analyses of intra-MCTS
distribution of FITC-BSA complexes. Fluorescence intensity
of each first layered cell or second layered cell was measured
from the obtained images by CLSM using the 40X objective.
Error bars in the graph represent the standard deviation, n =
14. *p<0.05 and **p<0.01.
(EPS)
Figure S2.  CLSM observation of each complex using
MCTS with specific endocytosis inhibitors. Effects of
inhibitors on the internalization of FITC-BSA complexes were
evaluated using Huh-7 MCTS by CLSM observation (40X
objective). The optical thickness and the distance of the
confocal section from the top of MCTS were 0.60 μm and 20
μm, respectively. A: MCTS was observed in the absence or
presence of sucrose (a clathrin-mediated endocytosis inhibitor)
under the condition of 30 min pre-incubation and 3h incubation
of FITC-BSA complexes. B: MCTS was observed in the
absence or presence of amiloride (a macropinocytosis inhibitor)
or filipin (a caveolae-mediated endocytosis inhibitor) under the
condition of 30 min pre-incubation and 1h incubation of FITC-
BSA complexes. The scale bars represent 50 μm.
(EPS)
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